Cong Xu
Non Executive ChairmanDr. Cong Xu, Ph.D., M.D. is Chairman of IMPACT Therapeutics, Inc and has been its Non-executive Director since September 23, 2025. Dr. Xu served as Director of IMPACT Therapeutics, Inc from July 2020 to September 23, 2025. Dr. Xu is Director of Shanghai Allist Pharmaceuticals Co. Ltd. from November 26, 2024. Dr. Xu serves as Executive Director and previously as Vice President at Lilly Asia Ventures (LAV). He serves as Non-Executive Director at ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. since October 14, 2020. Prior to joining LAV, he worked as Medical Director Associate in Oncology at Eli Lilly and Company and also lead regional clinical development for a number of oncology molecules including blockbuster abemaciclib. Prior to that, he was a U.S. Board Certified Physician. Dr. Xu has many years of experience in the biomedical and financial industries. Prior to joining our Group, Dr. Xu joined Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, which is a subsidiary of Eli Lilly and Company, a company listed on the New York Stock Exchange (“NYSE”) (stock code: LLY), in August 2012. Dr. Xu has been serving as a non-executive director of EdiGene Inc. and NovoDodex Biopharmaceuticals Co., Ltd. since August 2018 and March 2021, respectively. He has also been serving as a director of Shanghai Kechow Pharma, Inc. since March 2024. He has served as a director of ArriVent BioPharma, Inc., a company listed on NASDAQ Global Market (stock code: AVBP) from January 2022 to December 2023. Dr. Xu obtained a bachelor’s degree in clinical medicine from Tongji Medical College of Huazhong University of Science and Technology in the PRC in June 2007 and a Ph.D. in biological sciences from Clemson University in the United States in May 2012. He also obtained a master’s degree in business administration from the University of British Columbia in May 2018.
Positions
- Company NameIMPACT Therapeutics, IncStock Code07630PositionNon Executive ChairmanColleagues
